News | February 11, 2021
SMS Pharmaceuticals Q3FY21 consolidated PAT up to Rs. 21.39 Cr
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
The inspection conducted by EDQM at its Visakhapatnam facility
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Subscribe To Our Newsletter & Stay Updated
